NR1I2 and hypertensive nephropathy: Similarly, elevated mRNA levels of drug-metabolizing enzymes and multidrug resistance proteins in hypertensive nephropathy (HN) have been attributed to aberrant PXR activation, potentially compromising the efficacy of combination pharmacotherapy [170].